Potent Statin Lowers Cardiovascular Deaths

Published Online: Saturday, May 1, 2004

Pfizer's statin Lipitor (atorvastatin) went against Bristol-Myers Squibb's Pravachol (pravastatin) in a major study reported in the New England Journal of Medicine (April 8, 2004). The findings showed that especially aggressive treatment with statin drugs, intended to drive low-density lipoprotein (LDL) cholesterol levels below the recommended 100 mg/dL for heart attack patients, prevents new heart attacks and saves lives.

To determine whether the LDL level was low enough, the researchers compared 2 strategies? 40 mg a day of pravastatin (the older statin) or 80 mg of atorvastatin (the newest cholesterol- lowering drug). For the study, 4162 individuals were randomly given statin treatment within 10 days of heart attacks or severe chest pains.

The results indicated that the benefits of atorvastatin emerged within the first month of treatment and were consistent throughout the 21/2- year study. For example, death rates from all causes were 28% lower among participants taking atorvastatin, who did better in every category but stroke. Overall, 26.3% of the patients taking pravastatin had died or experienced a variety of other heart problems?including new heart attacks, bypass surgery, or chest pain? compared with 22.4% of patients on atorvastatin, for a 16% reduction in risk, said lead author Christopher Cannon, MD.

The message is that physicians should immediately begin using a more aggressive treatment before any eligible patient is discharged from the hospital, according to Dr. Cannon and other experts.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues